Kornimate/medical-research-clean huggingface dataset:
quad helix and correction of mandibular asymmetry

Conditions: Mandibular Asymmetry; Functional Shift of the Mandible

Summary: to compare the effectiveness of the quad helix, an orthopaedic conventional appliance, in the correction of skeletal mandibular asymmetry, on frontal x-ray, in subjects treated before or after 7 years.

introduction : unilateral posterior crossbite (upcb), often from dysfunctional and para-functional causes, leads to positional mandibular asymmetries that can develop at a very young age into skeletal mandibular deviation; hence the interest of early maxillary expansion. the purpose of this retrospective study was to compare the impact of maxillary expansion by quad helix (qh) on mandibular skeletal asymmetry correction before and after 7 years of age. materials and methods : all children with upcb and skeletal mandibular asymmetry, who were treated by qh in the orthodontic department between february 2017 and august 2018 and who have done a radiography file at baseline (t0) and 12 months later (t1) have been included. the patients were divided into two groups according to age: under 7 years of age (early group g1) with qh adjusted on second primary molars and over up to 13 years old (late group g2) with qh adjusted on first permanent molars. the differences between the right and left sides of the mandible in corpus length l (main eligibility criterion) and ramus height h (secondary criterion) were compared between groups. x² test, fisher's exact test and wilcoxon rank-sum tests were used for baseline comparisons. a multifactorial analysis allowing adjustment on possible confounding factors was used with r software at a significance level of 5%.

Eligibility criteria:
inclusion criteria: * unilateral posterior crossbite (at least one tooth) and skeletal mandibular asymmetry * treated by quad helix in the orthodontic department of the chu montpellier * with frontal x-rays available at baseline and 12months later exclusion criteria: * incomplete file * inadequate quality of x-rays

Keywords: early treatment posterior unilateral cross bite quad helix
chiropractic manipulation and medical care for low back pain

Conditions: Low Back Pain

Summary: the investigators will be comparing the effectiveness of two types of chiropractic manipulation and standard medical care for patients with a recent onset of low back pain. the two types of chiropractic treatments being compared will be hands-on (manual) manipulation and mechanical-assisted (activator) manipulation. the standard medical care will consist of a medical examination and prescription for over-the-counter anti-inflammatory medication.


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years of age * ability to read and write english * experiencing a new episode of low back pain (lbp) with onset in the past 3 months * oswestry disability index score between 20-70 points (0-100 scale) * numeric pain rating score between 3-8 points (0-10 scale) exclusion criteria: * prior history of lumbar spine surgery * history of unstable spondylolisthesis, spinal stenosis, or scoliosis \> 20° * signs or symptoms suggestive of nerve root tension and/or neurological deficit in the lower extremity * history of metastatic cancer, osteoporosis, long-term corticosteroid use, or any other red flags of serious illness including the following: unexplained weight loss of \>10% of body weight, spinal pain associated with fever, and severe night pain unrelieved by medication * receiving any physical therapy, chiropractic therapy, or any other manual therapy for this episode of lbp (within the past 3 months) * receiving any on-going medical care for this episode of low back pain * current use of opiate or other prescription medications for low back pain

Keywords: manipulation chiropractic low back pain
comparing different regimens for eradication of helicobacter pylori in kuwait

Conditions: Helicobacter Pylori Infection

Summary: eradication of h. pylori reduces morbidity in patients with chronic gastritis and can prevent gastric cancer. we aimed to evaluate the efficacy of clarithromycin-based triple therapy and non-bismuth based quadruple therapy for eradicating h. pylori in patients with chronic gastritis in kuwait.

helicobacter pylori (h. pylori) induced chronic infection is associated with peptic ulcer, chronic gastritis, gastric cancer, and increasing antibiotic resistance. eradication of h. pylori reduces morbidity in patients with chronic gastritis and can prevent gastric cancer in the high-risk population. we aimed to evaluate the efficacy of clarithromycin-based triple therapy and non-bismuth based quadruple therapy for eradicating h. pylori in patients with chronic gastritis in kuwait. we enrolled treatment-naive dyspeptic patients with gastric biopsy-proven chronic gastritis secondary to h. pylori in a prospective, open-label, randomized study conducted at the gastroenterology outpatient clinics of haya habeeb gastroenterology center in kuwait. patients were randomized into two groups: the first group received the standard triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days; and the second group received quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days. all patients were tested for the eradication of h. pylori by carbon-13 urea breath test (13c-ubt) one month after completion of eradication therapy.

Eligibility criteria:
inclusion criteria: * male and female dyspeptic subjects aged ≥18 years with any nationality * patients with gastric biopsy-proven h. pylori related chronic gastritis and no other abnormalities in the upper gastrointestinal tract upon endoscopy * patients who were naive to treatment for h. pylori infection. exclusion criteria: * pregnant or breastfeeding females * patients who were previously treated for h. pylori infection * patients who received any antibiotics, bismuth or acid-suppressant drugs within the last month
study of genistein in reducing side effects of superficial bladder cancer treatment

Conditions: Bladder Cancer

Summary: patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. intravesical therapy can cause many lower urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of treatment. there have been a number of studies that suggest a chemical found in soy beans may be able to help with these side effects. this chemical is called genistein and can be extracted and given to study subjects in pill form. in this study, the investigators would like to have patients placed into two different groups. one group would take genistein and the other group would take a placebo, a sugar pill that looks like the genistein pill. in doing this study the investigators hope to explore the findings from other studies to see if lower urinary tract symptoms are reduced and to see if recurrence rates for patients are affected by genistein. the study would take about four and a half months total.

patients who are treated with bacillus calmette-guerin (bcg) intravesical therapy for non-muscle invasive (tat1) tis superficial bladder cancer often develop adverse effects (urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and result in poor quality of life. genistein is a nutritional supplement with anti-inflammatory properties which might help alleviate adverse effects of intravesical therapy that are due to inflammation. additionally, genistein also has anti-tumor and immunopotentiating properties and has been shown to have no known side effects. our hypothesis is that genistein given together with bcg intravesical therapy will reduce its adverse effects and improve the efficacy of therapy. patients (n=88) scheduled for intravesical therapy will be randomly assigned to take 30 mg tablets po tid of genistein supplement (n=44) or placebo (n=44) during therapy and one month post therapy.

Eligibility criteria:
inclusion criteria: 1. male or female gender 2. 18 years or older 3. diagnosis of superficial bladder cancer 4. scheduled for induction bcg intravesical therapy 5. willing and able to give blood sample 6. willing and able to fill out a pill diary to ensure compliance 7. willing and able to sign informed consent 8. birth control is not required for this study! exclusion criteria: 1. patients who are pregnant 2. diagnosis of muscle-invasive bladder cancer 3. unwillingness to follow study protocol and compliance procedures 4. hiv positive or immunocompromised 5. receiving concurrent immunotherapy or chemotherapy 6. presence of concurrent second cancer (active, not history)
singapore's health outcomes after critical illness in kids

Conditions: Pediatric ALL; Critical Illness; Post Intensive Care Unit Syndrome

Summary: what is the problem? every year about 2.5 million children are affected by critical illness and require admission to the pediatric intensive care unit (picu). however, both children and their parents may encounter difficulties after critical illness. children affected physically may have difficulties in breathing, eating, and drinking. parents have reported feeling symptoms of stress such as nightmares and excessive worries after picu discharge. currently, the investigators do not know when and how the problems unfold and what harm does it cause. without this information, healthcare professionals are not equipped to support these families after picu discharge. research plan? to understand how critical illness could affect the physical, emotional, and social experiences of children age 1 month to 18 years of age and their parents in the first 6 months after a picu admission. 144 children and their parents will be followed from the time of picu admission to 6 months after discharge. children and their parents will complete surveys to measure physical, social, emotional and function outcomes. a total of 12 families will be interviewed at 1 and 3 months after picu discharge. using the data provided to map out any trend or changes in this information over time. why is this study important? to better understand the experience and health consequences of children and their parents in the first six months after picu admission. this information would help to identify potential areas to improve the negative consequence of children and their families after a severe illness. results will be shared to the picu survivors and their families, national organizations, international pediatric intensive care community to improve the experiences and health outcomes following a picu admission.


Eligibility criteria:
child inclusion criteria: * aged 1 month to 18 years at the point of picu admission * picu total length of stay (los) ≥ 48 hours at the point of picu discharge parents inclusion criteria: * (a) parent or legal guardian; (b) cohabits with the child * for the family home to be the planned location following hospital discharge. exclusion criteria: * opted for a "do not resuscitate" status for their child and/or * had participated in the current study in a previous picu admission within the recruitment period.

Keywords: critical illness family race ethnicity health outcomes
a clinical study to assess the effects of kb295 in patients with ulcerative colitis (uc) on gut microbiota structure and function

Conditions: Ulcerative Colitis

Summary: this exploratory, open-label clinical study aims to explore the effects of kb295, a novel glycan, on adult patients with ulcerative colitis (uc) presenting with mild-to-moderate uc symptoms


Eligibility criteria:
inclusion criteria: * be male or female, ≥18 and ≤75 years of age * confirmed diagnosis of uc (\>6 months) by endoscopy * mild-to-moderate uc with at least 4 weeks of uc symptomatology prior to screening * stable medication regimen for at least 2 weeks prior to screening, if on medication for uc exclusion criteria: * possible or confirmed diagnosis of crohn's disease or indeterminate disease * history of isolated distal proctitis * use of any antidiarrheal medications within the last 1 week prior to screening * antibiotic treatment within the past 28 days prior to screening * any non-uc related immunosuppressive medications other than purine analogs. systemic corticosteroids including prednisone \> 10 mg per day are excluded. * major intra-abdominal surgery related to the bowel within 24 weeks prior to the screening period and/or planned invasive surgery/hospitalization during the study * major medical comorbidities, or other conditions in the opinion of the pi, that might impact the patient's safety or compliance, or the interpretation of the study results * treatment with any other investigational drugs within 28 days prior to the screening visit

Keywords: microbiome ulcerative colitis kaleido kaleido biosciences kb295 oligosaccharide glycan pathogens microbiome metabolic therapy mmt mild-to-moderate uc
a trial evaluating the efficacy and safety of hld200 in children with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study will examine the efficacy and safety of hld200 in patients age 6-12 years with adhd using a classroom study design.

the study consists of two distinct treatment phases. the first is the 6-week open-label, treatment optimization phase during which subjects are titrated to an optimal daily dose of hld200. subjects are then randomized to receive either optimal hld200 or matched placebo treatment for an additional week prior to final testing during a laboratory school day.

Eligibility criteria:
inclusion criteria: * male and female children (6-12 years at study entry) * previous diagnosis of adhd and confirmation using the mini international neuropsychiatric interview for children and adolescents (mini-kid) * able to swallow treatment capsules * available for entire study period * provision of informed consent (from the parent\[s\] and/or legal representative\[s\]) and assent (from the subject) * female subjects of childbearing potential (i.e., post-menarche) required to have a negative result on urine pregnancy test (and will be given specific instructions for avoiding pregnancy during trial). exclusion criteria: * any known history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, ophthalmologic disease * presence of any significant physical or organ abnormality * any illness during the 4 weeks before this study * comorbid psychiatric diagnosis that may affect subject safety or confound results (e.g., psychosis, bipolar disorder) * known history of severe asthma (in the opinion of the investigator) unless deemed currently controlled * known history of severe allergic reaction to mph * known history of seizures (except febrile seizures prior to age 5), anorexia nervosa, bulimia or current diagnosis or family history of tourette's disorder * subject who are severely underweight or overweight (in the opinion of the investigator) * any clinical laboratory value outside of the acceptable ranges, unless deemed ncs significant per the investigator * positive history for hepatitis b, hepatitis c or human immunodeficiency virus (hiv) * positive screening for illicit drug use, and/or current health conditions or use of medications that might confound the results of the study or increase risk to the subject * use of prescription medications (except adhd medications) within 7 days and over-the-counter medications (except birth control) within the 3 days preceding study enrollment, unless deemed acceptable by the investigator and clinical or medical monitor * participation in clinical trial with an investigational drug within the 30 days preceding study enrollment * current suicidal ideation or history of suicidality determined as a significant finding on the c-ssrs by the investigator (baseline c-ssrs for adolescents; pediatric baseline c-ssrs for children).
randomized controlled trial comparing adult to pediatric colonoscope in obese patients.

Conditions: Obesity (body Mass Index &amp;amp;gt;30 Kg/m2); Screening Colonoscopy

Summary: the goal of this study is to test which colonoscope works best in people who are above a certain body mass index. currently, both pediatric and adult colonoscopes are accepted as standard treatments in colonoscopies. doctors pick which one to use based on personal preference and what is available.


Eligibility criteria:
inclusion criteria: * bmi greater than 30 * screening and surveillance colonoscopy exclusion criteria: * colon surgery * therapeutic colonoscopy * inflammatory bowel disease * terminated procedure due to stool burden, stenosis, or obstructive mass. * colonoscopy for anemia * history of incomplete colonoscopy due to technical difficulties

Keywords: obesity screening colonoscopy
natural history and biological study of netherton syndrome

Conditions: Netherton Syndrome; Healthy

Summary: this study aims at studying the natural history of netherton syndrome (ns), to identify the consequences of lekti deficiency on the immune system and to characterize new molecular mechanisms involved in the disease.


Eligibility criteria:
inclusion criteria: * adult or child (no age limit) * confirmed diagnosis of netherton syndrome * signed informed consent form for the patient or his legal representative exclusion criteria: * bleeding disorder precluding skin biopsy

Keywords: netherton syndrome immune system skin barrier
vital root amputation in molars with advanced periodontal furcation involvement: a preliminary study

Conditions: Periodontal Diseases; Furcation Defects

Summary: the goal of this clinical trial is to test in 10 patients with advanced furcation involvement on molars. the main question\[s\] it aims to answer are: • is it possible to carry out root resection without endodontic treatment on molars? tooth vitality will be checked (positive response to cold test). root resection will be carried out under local anestesia. following visits will be carried out for re-evaluation/maintenance according to clinical care every 3 mounths until 3 years follow-up.


Eligibility criteria:
inclusion criteria: * patient diagnosed with stage iii-iv periodontitis * compliantpatient, as shown by full mouth plaque score\<30% * previous non-surgical periodontal therapy within 6 mounths * maxillary or mandibular molar affected by periodontal furcation involvement and scheduled for root resection * positive to sensibility testing (cold/electric pulp tests) * no prosthesis or large restorations * sufficiently divergent roots to make root resection feasible * root trunk lenght at 3 mm as measured in periapical radiograph exclusion criteria: * systemic contraindications to perform periodontal surgery/root resection * fused roots * presence of periapical radiolucency * furcation class iii affecting all roots of maxillary molar

Keywords: periodontal disease furcation defects root resection
safety and tolerability of nitro for radial artery dilation

Conditions: Artery; Dilatation

Summary: phase 1, single-center, open-label clinical study to assess the safety and efficacy of topical nitroglycerin on dilation of the radial artery. subjects will receive nitroglycerin ointment prior to scheduled pci and radial artery measurements will be performed to determine mean increase in radial artery diameter at several time points. there will be 20 subjects enrolled in this study.

this is a phase i study evaluating the safety, tolerability, and efficacy of topical nitroglycerin prior to percutaneous coronary intervention (pci). although the ultimate plan is to evaluate this intervention vs placebo, it is important to first determine whether topical nitroglycerin not only is safe for patients, but whether it effectively dilates the radial artery. given that patients who receive topical nitroglycerin applied to the chest for other reasons (angina or acute coronary syndrome, hypertension, etc) have reported headaches and/or have experienced decreased blood pressure, it is important to determine whether these noted side effects are present when nitroglycerin ointment is applied to the arm. prior to initiating any study procedures, we will perform a barbeau test to determine normal blood flow through the radial artery and collateral circulation from the ulnar artery through the palmar arch. after the ointment is applied, we will also be measuring the dimensions of the radial artery for the degree of dilation in order to determine whether topical nitroglycerin is indeed a possible method for increasing the rate of pci performed using the transradial approach (tra).

Eligibility criteria:
inclusion criteria: * scheduled to undergo pci using tra in the cardiac catheterization laboratory exclusion criteria: 1. known nitrate allergy 2. baseline hypotension with systolic blood pressure \<90mmhg 3. absence of radial artery blood flow in one or both arms 4. presence or history of liver, rheumatologic, or chronic kidney disease 5. current treatment with any vasodilator therapy (eg. sildenafil) 6. radial artery catheterization \<30 days prior to enrollment 7. active site infection 8. av-fistula or prior radial artery harvest for bypass surgery 9. abnormal barbeau test

Keywords: cardiac catheterization transradial approach nitroglycerin
alrn-6924 in patients with advanced solid tumors or lymphomas

Conditions: Solid Tumor; Lymphoma; Peripheral T-Cell Lymphoma

Summary: this study evaluates the anti-tumor effects of alrn-6924 in patients with advanced solid tumors or lymphomas with wt tp53.

open label, multi center, phase 1 (dose escalation) and phase 2a (dose expansion) study design to evaluate safety, tolerability, pk, pd and anti-tumor effects of alrn-6924, alone or in combination with palbociclib, in patients with advanced solid tumors or lymphomas with wild-type (wt) tp53. alrn-6924 is a stabilized cell-permeating peptide designed to disrupt the interaction between the p53 tumor suppressor protein and its predominant endogenous inhibitors, murine double minute 2 (mdm2) and murine double minute x (mdmx). the phase 1 portion of the study will enroll adults with histologically or cytologically confirmed malignancies that are metastatic or unresectable and for which standard treatment(s) are not available or are no longer effective. the phase 2a portion of the study consists of separate cohorts that will enroll distinct groups of patients with specific solid tumors and/or lymphomas to further investigate the clinical safety profile and potential efficacy of alrn-6924 alone or in a combination regimen. treatment will continue until unacceptable toxicity, patient or physician decision to discontinue therapy or disease progression that is either symptomatic, rapidly progressive, requires urgent intervention or is associated with a decline in performance status. patients with ptcl have been selected as a group to be further studied in phase 2a. patients with mdm2-amplified or mdm2/cdk4-co-amplified solid tumors have been selected as another group to be further studied in phase 2a.

Eligibility criteria:
inclusion criteria * histologically or cytologically confirmed solid tumor or lymphoma that is not amenable to standard therapies. * cohort specific biomarkers, including confirmed or anticipated wt tp53 (phase 1 and ptcl expansion cohorts) and mdm2-amplification or mdm2/cdk4-co-amplification (solid tumor expansion cohort) * at least one target lesion that is measurable by recist 1.1, rano or iwg 2014, as appropriate for tumor type * ecog (eastern cooperative oncology group) performance status 0-1 * adequate coagulation and hematologic function * adequate hepatic and renal function * sufficient wash out from prior therapies and recovery from all significant acute toxicities key exclusion criteria * prior treatment with an mdm2 inhibitor, with protocol specified exceptions * known hypersensitivity to any study drug component * protocol specified cardiovascular risk factors * clinically significant gastrointestinal bleeding within 6 months * clinically significant third-space fluid accumulation * active uncontrolled infection, including hiv/aids or hepatitis b or c * hpv positive tumors * second malignancy within two years, with protocol specified exceptions * pregnancy or lactation